Verma Saurav, Kumar Nipun, Meel Rachna, Sen Seema, Kashyap Seema, Sharma Sanjay, Pushker Neelam, Pushpam Deepam, Bakhshi Sameer
Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Department of Ophthalmology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Ocul Oncol Pathol. 2021 Sep;7(4):251-256. doi: 10.1159/000515857. Epub 2021 May 5.
There are sparse data on neoadjuvant systemic chemotherapy (NACT) in eyelid sebaceous gland carcinoma (SGC). The aim of this study was to evaluate efficacy and outcomes with NACT in eyelid SGC. We retrospectively analyzed 8 patients who received platinum-based NACT. The median number of cycles per patient was 4 (range, 3-5). The mean percentage reduction of tumor diameter after NACT was 71% (range, 30-100%). Two patients had a radiological complete response (CR). After NACT, surgical treatment for residual tumor was performed in 5 cases. One patient had a pathological CR and is recurrence free for 11 years. After a mean follow-up period of 44.5 months (range, 9-109), tumor recurrence occurred in 4 cases. Among these 4 cases, 3 were rechallenged with the same regimen and all responded. Systemic NACT has a role in eyelid SGC, downstages the tumor, and allows less aggressive and organ-sparing surgeries, warranting a prospective study.
关于眼睑皮脂腺癌（SGC）新辅助全身化疗（NACT）的数据较少。本研究的目的是评估NACT治疗眼睑SGC的疗效和结果。我们回顾性分析了8例接受铂类NACT的患者。每位患者的中位化疗周期数为4个（范围3 - 5个）。NACT后肿瘤直径的平均缩小百分比为71%（范围30% - 100%）。2例患者达到影像学完全缓解（CR）。NACT后，5例患者对残留肿瘤进行了手术治疗。1例患者达到病理CR，且11年无复发。平均随访44.5个月（范围9 - 109个月）后，4例出现肿瘤复发。在这4例患者中，3例再次接受相同方案治疗且均有反应。全身NACT在眼睑SGC治疗中具有作用，可使肿瘤降期，并允许进行侵袭性较小的保留器官手术，有必要进行前瞻性研究。
